ロボティック・バイオロジー・インスティテュート Company Profile

A clinical research plan utilizing the general-purpose humanoid robot LabDroid "Mahoro" has been approved. The application for the clinical research on "Transplantation of allogeneic iPS cell-derived RPE cell aggregates for retinal pigment epithelium (RPE) deficiency" by the Kobe City Medical Center General Hospital, a local independent administrative corporation, was approved at the meeting of the Ministry of Health, Labour and Welfare's Council on Health Science on February 17, 2022. This clinical research includes procedures using the general-purpose humanoid robot LabDroid "Mahoro," developed by RBI, during the cell culture process. So far, RBI has been working on the automation, enhancement, and next-generation development of cell manufacturing using robots and AI in partnership with the Vision Care Group (Vision Care Co., Ltd., VC Gene Therapy Co., Ltd., VC Cell Therapy Co., Ltd., headquartered in Chuo-ku, Kobe City, Hyogo Prefecture, President: Masayo Takahashi), and this has led to the utilization of these achievements in clinical research. For more details, please refer to the press release from the Vision Care Group. https://www.vcct.jp/news/20220218